The relationshipbetween AGO2 mRNA expression and shRNA screen quality was weaker in the breast cancer screens (Supplementary Fig S3), which may reflect somecombination of generally better performing screens in breast cancer cell lines—withcorresponding lower variability—and the fact that the expression data were collected on adifferent microarray platform. This evidence concerns the gene AGO2 and breast cancer.